Low-dose Challenge Model With Enterotoxigenic E Coli

NCT ID: NCT00844493

Last Updated: 2014-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2013-06-30

Brief Summary

This study will validate a model for testing new vaccines designed to protect against intestinal infections with enterotoxigenic Escherichia coli (ETEC). ETEC is one of the most common causes of diarrhea in developing countries and is a common cause of travelers diarrhea. Vaccines are now being developed and their development will be facilitated if we have a valid model for testing these vaccines in human volunteers. We anticipate that the new vaccines will be given to volunteers and they will then be given a dose of virulent ETEC bacteria. If the vaccine is effective, the volunteers should not development diarrhea, but if the vaccine is not effective, the volunteers will have diarrhea for a few days.

During this study, we will validate a minimum dose of virulent ETEC bacteria which is sufficient to cause diarrhea in healthy adult volunteers and to identify conditions that can make this model reliable.

We will also determine, in a follow-up group of volunteers, if being exposed to the ETEC bacteria previously will protect against a subsequent illness when they are exposed to the same bacteria a second time. We believe that the previously exposed group will be protected and we will study the immune response to these exposures to help design vaccines that can accomplish this kind of protection.

Detailed Description

This is a study in which healthy adult inpatient volunteers will be challenged with Escherichia coli, strain H10407 using different conditions. The study has the following objectives.

1. To identify a revised set of procedures for the ETEC H10407 challenge model that will allow for an inoculum dose <108 organisms, and that will cause diarrhea in 50% or more of subjects without causing high output diarrhea, as determined by stool output volumes or signs and symptoms associated with hypovolemia.

2. To measure mucosal and systemic immune responses to ETEC H10407 in naïve and immune subjects.

3. To determine the extent to which recent enteric illness due to ETEC H10407will protect subjects against diarrhea when re-challenged with H10407.

4. To determine the extent to which mucosal and/or systemic antibody responses following ETEC H10407diarrhea are predictive of protection in a re-challenge study.

The study is divided into 4 cohorts. The first cohort will test four conditions of dose and buffer for the challenge. Using the conditions that appear to be best, a larger number of volunteers will be given this challenge to validate these conditions. The third group will be divided between some volunteers who had been ill during previous studies and some who have not been exposed before.

Specimens will be obtained to determine the extent of excretion of the challenge strain and the immune responses to the challenge. These will include measures of both systemic and local intestinal immunity.

Update as of May 2010:

The clinical portion of the study has been completed and is no longer recruiting. The overall results were presented at two meetings including the Vaccines for Enteric Diseases in Spain in 2009 and the US-Japan Medical Science conference on Cholera and Enteric Disease in San Diego in 2009. Volunteers who received the lower dose (7 logs), along with an overnight fast developed diarrhea with an attack rate of >75%. Volunteers who were challenged a second time with this dose were protected from subsequent illness. Immunological assessment of the volunteers is continuing.

Update as of November 2011 Results of the first three cohorts were published in 2011 (see citation below). A fourth cohort is planned to be enrolled to evaluate the virulence of an even lower dose of 5 and 6 logs of E coli. The same procedures will be carried out as with earlier cohorts.

Update as of April 2013 Following challenge with 5 or 6 logs of strain H10407, the attack rates were lower (approximately 30%). Among those volunteers who did develop illness, the severity was the same as with higher doses. completion of these lower doses completes the dose response curve for H10407. For future challenge studies, 7 logs of H10407 with bicarbonate buffer will be used.

Conditions

Diarrhea

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

H10407 challenge 1

7 or 8 logs of E. coli strain H10407 with CeraVacx buffer

Group Type: EXPERIMENTAL

E coli strain H10407 and buffer

Intervention Type: BIOLOGICAL

7 or 8 logs of the bacteria with bicarbonate buffer

H10407 challenge 2

7 or 8 logs of E. coli strain H10407 with bicarbonate buffer

Group Type: EXPERIMENTAL

E coli strain H10407 and buffer

Intervention Type: BIOLOGICAL

Bacteria in a dose of 8 logs with CeraVacx buffer

H10407 challenge 3

6 logs of E. coli H10407 with bicarbonate buffer

Group Type: EXPERIMENTAL

E coli strain H10407 and buffer

Intervention Type: BIOLOGICAL

Bacteria in a dose of 7 logs and CeraVacx buffer

H10407 challenge 4

5 logs of E. coli H10407 with bicarbonate buffer

Group Type: EXPERIMENTAL

E coli H10407 and buffer

Intervention Type: BIOLOGICAL

Bacteria in a dose of 8 logs with bicarbonate buffer

Interventions

E coli strain H10407 and buffer

7 or 8 logs of the bacteria with bicarbonate buffer

Intervention Type: BIOLOGICAL

E coli strain H10407 and buffer

Bacteria in a dose of 8 logs with CeraVacx buffer

Intervention Type: BIOLOGICAL

E coli strain H10407 and buffer

Bacteria in a dose of 7 logs and CeraVacx buffer

Intervention Type: BIOLOGICAL

E coli H10407 and buffer

Bacteria in a dose of 8 logs with bicarbonate buffer

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female between 18 and 45 years of age, inclusive.

2. General good health, as determined by physical exam, laboratory testing, and medical history.

3. Laboratory values within acceptable range for complete blood count (CBC), Alanine Aminotransferase (ALT), and serum creatinine as determined by PI.

4. Demonstrate comprehension of the protocol procedures and knowledge of ETEC illness by passing a written examination (pass grade ≥ 70%)

5. Able and willing to sign an informed consent.

6. Available to participate for the length of the study.

7. Female only: Females of childbearing potential will use an effective method of contraception during the study, including abstinence, hormonal contraception, barrier, implantables or injectables.

Exclusion Criteria

1. Presence of a clinically significant medical condition (including but not limited to any chronic illnesses, immunosuppressive illness, cancer, diabetes, gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease)

2. Evidence of immunoglobulin A (IgA) deficiency (serum IgA <5 or limit of detection of assay)

3. Evidence of HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), by medical history or laboratory testing.

4. Symptoms consistent with Traveler's Diarrhea concurrent with travel to countries where ETEC or cholera infection is endemic (most of the developing world) within two years prior to receipt of investigational agent, OR planned travel to endemic countries during the length of the trial.

5. History of significant psychiatric illness requiring hospitalization or any suicide attempts within the past 2 years.

6. History of significant drug or alcohol abuse requiring hospitalization or rehabilitation within the past 2 years.

7. Evidence of significant drug abuse, as determined by the Principal Investigator, on toxicity screening.

8. Fewer than 3 stools per week or more than 3 stools per day as the usual frequency; loose or liquid stools other than on an occasional basis.

9. History of allergic reaction to fluoroquinolones, cotrimoxazole, or ampicillin/penicillin (excluded if allergic to two of three).

10. History of diarrhea in the 2 weeks prior to receipt of investigational agent.

11. Weekly use of laxatives or any agent that increases gastric pH.

12. Use of antibiotics during the 7 days prior to receipt of investigational agent.

13. Use of proton pump inhibitors, H2 blockers, or antacids within 48 hours of receipt of investigational agent.

14. History of vaccination for or ingestion of ETEC, cholera, or heat labile toxin (LT) toxin within 5 years.*

15. History of participation in prior ETEC H10407 research studies.*

16. Use of any other investigational product within 30 days preceding the receipt of investigational agent, or planned use during the active study period.

17. Use of any medication known to affect the immune function (e.g., corticosteroids) within 30 days preceding receipt of investigational agent or planned use during the active study period. (Topical and intra-articular steroids will not exclude subjects).

18. Any other condition, which in the opinion of the investigator, could affect subject safety or interfere with the trial.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

PATH Vaccine Solutions

OTHER

Sponsor Role: collaborator

Johns Hopkins Bloomberg School of Public Health

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clayton Harro, M.D.

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Bloomberg School of Public Health

Locations

Center for Immunization Research, Johns Hopkins Bloomberg School of Public Heatlh

Baltimore, Maryland, United States

Countries

United States

References

McKenzie R, Bourgeois AL, Engstrom F, Hall E, Chang HS, Gomes JG, Kyle JL, Cassels F, Turner AK, Randall R, Darsley M, Lee C, Bedford P, Shimko J, Sack DA. Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults. Infect Immun. 2006 Feb;74(2):994-1000. doi: 10.1128/IAI.74.2.994-1000.2006.

Reference Type: BACKGROUND

PMID: 16428745 (View on PubMed)

Sack DA, Shimko J, Sack RB, Gomes JG, MacLeod K, O'Sullivan D, Spriggs D. Comparison of alternative buffers for use with a new live oral cholera vaccine, Peru-15, in outpatient volunteers. Infect Immun. 1997 Jun;65(6):2107-11. doi: 10.1128/iai.65.6.2107-2111.1997.

Reference Type: BACKGROUND

PMID: 9169739 (View on PubMed)

DuPont HL, Formal SB, Hornick RB, Snyder MJ, Libonati JP, Sheahan DG, LaBrec EH, Kalas JP. Pathogenesis of Escherichia coli diarrhea. N Engl J Med. 1971 Jul 1;285(1):1-9. doi: 10.1056/NEJM197107012850101. No abstract available.

Reference Type: BACKGROUND

PMID: 4996788 (View on PubMed)

Qadri F, Saha A, Ahmed T, Al Tarique A, Begum YA, Svennerholm AM. Disease burden due to enterotoxigenic Escherichia coli in the first 2 years of life in an urban community in Bangladesh. Infect Immun. 2007 Aug;75(8):3961-8. doi: 10.1128/IAI.00459-07. Epub 2007 Jun 4.

Reference Type: BACKGROUND

PMID: 17548483 (View on PubMed)

Qadri F, Ahmed T, Ahmed F, Begum YA, Sack DA, Svennerholm AM; PTE Study Group. Reduced doses of oral killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine is safe and immunogenic in Bangladeshi infants 6-17 months of age: dosing studies in different age groups. Vaccine. 2006 Mar 6;24(10):1726-33. doi: 10.1016/j.vaccine.2005.08.110. Epub 2005 Oct 10.

Reference Type: BACKGROUND

PMID: 16257098 (View on PubMed)

Qadri F, Svennerholm AM, Faruque AS, Sack RB. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev. 2005 Jul;18(3):465-83. doi: 10.1128/CMR.18.3.465-483.2005.

Reference Type: BACKGROUND

PMID: 16020685 (View on PubMed)

Harro C, Chakraborty S, Feller A, DeNearing B, Cage A, Ram M, Lundgren A, Svennerholm AM, Bourgeois AL, Walker RI, Sack DA. Refinement of a human challenge model for evaluation of enterotoxigenic Escherichia coli vaccines. Clin Vaccine Immunol. 2011 Oct;18(10):1719-27. doi: 10.1128/CVI.05194-11. Epub 2011 Aug 18.

Reference Type: RESULT

PMID: 21852546 (View on PubMed)

Chakraborty S, Harro C, DeNearing B, Brubaker J, Connor S, Maier N, Dally L, Flores J, Bourgeois AL, Walker R, Sack DA. Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers. PLoS Negl Trop Dis. 2018 Apr 27;12(4):e0006442. doi: 10.1371/journal.pntd.0006442. eCollection 2018 Apr.

Reference Type: DERIVED

PMID: 29702652 (View on PubMed)

Related Links

http://www.icddrb.org

web site for the International Centre for Diarrhoeal Disease Research, Bangladesh where much of the work on ETEC is done

Other Identifiers

CIR259

Identifier Type: -

Identifier Source: org_study_id